Tectonic Therapeutic (TECX) shares climbed 90% in Thursday's premarket session after the company said a phase 1b trial showed that TX45 improved left ventricular function and pulmonary hemodynamics.
The biotech firm said TX45 was well tolerated with no serious or severe adverse events, discontinuations, infusion reactions, or drug-related adverse events.
"These interim results show that TX45 achieved improvements in hemodynamics which met and exceeded our prespecified objectives," Chief Executive Alise Reicin said in a release.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。